NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03556839,Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix,https://clinicaltrials.gov/study/NCT03556839,BEATcc,ACTIVE_NOT_RECRUITING,"The study will integrate the efficacy of combining the anti programmed death-ligand 1 (anti-PD-L1) agent atezolizumab with the current standard of care in Stage IVB , persistent or recurrent carcinoma of the cervix, namely cisplatin or carboplatin/paclitaxel/bevacizumab. It will be explored the combination of bevacizumab plus atezolizumab, with no patient selection based on PD-L1 expression, allowing an all-comer assessment of atezolizumab activity.

The study is a randomized open label phase III trial to investigate the impact of atezolizumab in combination with bevacizumab and cisplatin or carboplatin /paclitaxel chemotherapy on overall survival and will employ the intent to treat principle, and random assignment to one of the 2 arms will be balanced according to disease histology (squamous cell carcinoma vs adenocarcinoma), prior platinum therapy as a radiation sensitizer (no prior cis-Radiotherapy (RT) versus prior cis-RT) and chemotherapy backbone (cisplatin vs carboplatin).

This trial will be run in an open label design due to the following considerations: the control arm is the standard of care for women diagnosed with metastatic, persistant or recurrent cervical cancer because of its impact on overall survival and the primary endpoint of the study is overall survival (OS), so blinding is not needed to ensure a robust assessment.",NO,"Carcinoma of the Cervix, Stage IVB",DRUG: Atezolizumab|DRUG: Bevacizumab|DRUG: Cisplatin/Carboplatin|DRUG: Paclitaxel,"Progression-free survival, Time from the date of randomization to the date of first documentation of disease progression or death due to any cause, whichever occurs first based on investigator assessment using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1), 48 months|Overall survival, Time from the date of randomization to the date of death due to any cause, 48 months","Objective Response Rate, Based on investigator assessment using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1), 48 months|Duration of response, Based on investigator assessment using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1), 48 months|Incidence of Treatment-Emergent Adverse Events of combining atezolizumab to chemotherapy plus bevacizumab compared to cisplatin or carboplatin/paclitaxel (CP) plus bevacizumab., Incidence, nature and severity of adverse events (AEs) assessed by CTCAE version 5.0, 48 months|First subsequent therapy, Time from randomization to first subsequent therapy or death due to any cause, 48 months|Progression-free survival 2, Time from randomization to the second event of disease progression per radiological criteria, start of a new line of therapy, due to symptomatic deterioration or to death due to any cause, 48 months|Patient-reported outcomes (PROs) of function and health related quality of life (HR-QOL) associated with atezolizumab + CP + bevacizumab compared to bevacizumab + CP alone, as measured by the functional and GHS/ HRQoL scales of EORTC QLQ-C30, Mean and mean changes from baseline score in patient function (role, physical) and GHS/HRQoL, by assessment timepoint and between treatment arms, as assessed by the functional and GHS/HRQoL scales of EORTC QLQ-C30., 48 months|Pharmacokinetics (PK) of atezolizumab, Serum concentration (Cmin) of atezolizumab, 36 months|Pharmacokinetics (PK) of atezolizumab, Serum concentration (Cmax) of atezolizumab, 36 months|Incidence of anti-therapeutic antibodies (ATAs), Incidence of ATAs during the study relative to the prevalence of ATAs at baseline, 36 months",,Grupo Español de Investigación en Cáncer de Ovario,ARCAGY/ GINECO GROUP|Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies|MaNGO|NSGO|Japanese Gynecologic Oncology Group|Gynecologic Oncology Group Foundation|AGO Study Group|Apices Soluciones S.L.|Hoffmann-La Roche,FEMALE,"ADULT, OLDER_ADULT",PHASE3,410,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,ENGOT-Cx10 / BEATcc|2018-000367-83|ENGOT-Cx10|GEICO 68-C|JGOG1084|GOG-3030|2024-514179-17-00,2018-09-25,2025-08,2025-08,2018-06-14,,2025-03-25,"Willis Knighton Cancer Center, Shreveport, Louisiana, 71103, United States|Massey Cancer Center, Richmond, Virginia, 980037, United States|ICO Paul Papin, Angers, 49055, France|CHU Jean Minjoz, Besancon, France|Institut Bergonié, Bordeaux, France|Centre François Baclesse, Caen, France|Centre Oscar Lambret, Lille, 59000, France|Centre Léon Bérard, Lyon, France|ICM Val d'Aurelle, Montpellier, France|Hôpital Privé du Confluent S.A.S., Nantes, France|Centre Antoine Lacassagne, Nice, France|Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, France|HEGP, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Centre CARIO-HPCA, Plerin, France|ICO Centre René Gauducheau, Saint-herblain, France|Hôpitaux Universitaires, Strasbourg, France|Institut Claudius Régaud, Toulouse, France|Gustave Roussy, Villejuif, France|Universitätsmedizin Mainz, Mainz, 55131, Germany|Helios-Klinikum Wuppertal, Wuppertal, 42283, Germany|Fondazione Del Piemonte Per L'Oncologia, Candiolo, Italy|Azienda Ospedaliero-Universitaria Di Ferrara, Ferrara, Italy|Ospedale Lecce 'Vito Fazzi', Lecce, Italy|ASST Lecco, Lecco, Italy|Irst Irccs, Meldola FC, Italy|Irccs S. Raffaele - Milano, Milano, Italy|Istituto Europeo di Oncologia, Milano, Italy|Ospedale San Gerardo, Monza, Italy|Istituto Nazionale Tumori Di Napoli Irccs Pascale, Napoli, Italy|Istituto Oncologico Veneto (IOV) IRCCS, Padova, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|AUSL Romagna - P.O. di Ravenna, Lugo, Faenza, Rimini e Cattolica, Ravenna, Italy|Azienda Usl - Irccs Di Reggio Emilia, Reggio Emilia, Italy|Policlinico Universitario A. Gemelli, Roma, Italy|AOU Città della Salute e della Scienza di Torino, Presidio Sant'Anna, Torino, Italy|Ospedale Ordine Mauriziano, Torino, Italy|Azienda Sanitaria Universitaria Integrata Di Udine, Udine, Italy|Kurume University Hospital, Fukuoka, Japan|Saitama medical university international medical center, Hidaka, Japan|Hokkaido Cancer Center, Hokkaido, Japan|Hyogo Cancer Center, Hyōgo, Japan|Cancer Institute Hospital, Koto-Ku, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Keio University Hospital, Tokyo, Japan|Haukeland University Hospital, Bergen, Norway|Oslo University Hospital, Oslo, Norway|University Hospital of North Norway, Tromsø, Norway|Intitut Català d' Oncolgia L' Hospitalet, Hospitalet de LLobregat, Barcelona, 08907, Spain|Parc Taulí, Sabadell, Barcelona, 08208, Spain|Hospital Universitario Donostia- Donostia Unibertsitate Ospitalea, Donostia, Gipuzkoa, 20014, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Islas Baleares, 07120, Spain|Hospital de la Vall d'Hebron, Barcelona, 08035, Spain|H. Clínic Barcelona, Barcelona, 08036, Spain|Hospital Reina Sofía Cordoba, Cordoba, 14004, Spain|ICO Girona, Girona, 17007, Spain|Hospital Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Clinico Universitario Virgen Arrixaca, Murcia, 30120, Spain|Complejo Hospitalario Regional de Málaga, Málaga, 29010, Spain|Hosptial Clinico Universitario de Santiago de Compostela, Santiago de Compostela, 15706, Spain|Hospital Virgen de la Salud, Toledo, 45004, Spain|Instituto Valenciano de Oncología, Valencia, 46009, Spain|Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain|Hospital Quirón de Valencia, Valencia, 46010, Spain|Hospital Miguel Servet, Zaragoza, 50009, Spain|Lindköping University Hospital, Linköping, Sweden|Skane University Hospital, Lund, Sweden|Karolinska University Hospital, Stockholm, Sweden|Uppsala University Hospital, Uppsala, Sweden",
